# BIIB033 In Acute Optic Neuritis (AON)

> **NCT01721161** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 82 (actual)

## Conditions studied

- Acute Optic Neuritis

## Interventions

- **BIOLOGICAL:** BIIB033 (anti-LINGO-1 mAb)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01721161
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2016-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721161, "BIIB033 In Acute Optic Neuritis (AON)". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT01721161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*